KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biomarin Pharmaceutical (BMRN) Equity Income (2017 - 2021)

Biomarin Pharmaceutical's Equity Income history spans 12 years, with the latest figure at $177000.0 for Q3 2021.

  • For the quarter ending Q3 2021, Equity Income rose 119.22% year-over-year to $177000.0, compared with a TTM value of -$278000.0 through Sep 2021, up 68.55%, and an annual FY2020 reading of -$6000.0, up 98.98% over the prior year.
  • Equity Income for Q3 2021 was $177000.0 at Biomarin Pharmaceutical, up from -$175000.0 in the prior quarter.
  • The five-year high for Equity Income was $1.1 million in Q4 2020, with the low at -$1.4 million in Q1 2021.
  • Average Equity Income over 5 years is -$185533.3, with a median of -$107000.0 recorded in 2018.
  • Year-over-year, Equity Income soared 519.57% in 2019 and then tumbled 1654.55% in 2021.
  • Tracing BMRN's Equity Income over 5 years: stood at -$220000.0 in 2017, then soared by 79.09% to -$46000.0 in 2018, then soared by 519.57% to $193000.0 in 2019, then surged by 454.92% to $1.1 million in 2020, then crashed by 83.47% to $177000.0 in 2021.
  • Per Business Quant, the three most recent readings for BMRN's Equity Income are $177000.0 (Q3 2021), -$175000.0 (Q2 2021), and -$1.4 million (Q1 2021).